The effectiveness of Coenzyme Q10 in mitigating symptoms of Parkinson's disease: a meta-analysis
Key Finding
CoQ10 supplementation (1200mg daily) significantly improved motor symptoms in Parkinson's disease patients.
Plain-English Summary
This meta-analysis evaluated six randomized controlled trials examining Coenzyme Q10 (CoQ10) supplementation in Parkinson's disease patients. Studies used doses ranging from 300-1200mg daily over treatment periods of 3-16 months.
Results showed that CoQ10 supplementation significantly improved motor symptoms in Parkinson's patients as measured by the Unified Parkinson's Disease Rating Scale. Benefits were more pronounced with higher doses (1200mg daily) and longer treatment durations.
CoQ10 is a vital component of mitochondrial energy production and also functions as a powerful antioxidant. The supplement may protect neurons from oxidative damage and improve cellular energy metabolism, which are both implicated in neurodegenerative diseases. While these findings specifically address Parkinson's disease, the neuroprotective properties of CoQ10 may have broader implications for brain health and cognitive function. The supplement was well-tolerated across all studies.